<p>賓夕法尼亞州普利茅斯會議——（商業資訊）——Harmony Biosciences Holdings, Inc.（納斯達克：HRMY）今天宣佈，將於 2026 年 2 月 24 日美國金融市場開盤前發佈 2025 年第四季度和全年財務業績。Harmony 將在 2026 年 2 月 24 日上午 8:30（東部時間）召開電話會議和網絡直播，以討論業績。</p>
<p>要參加此次電話會議，請撥打 800-274-7083（國內）或 203-518-9786（國際），並引用密碼 HRMYQ425。建議您至少在會議開始前 10 分鐘撥入。</p>
<p>此次電話會議的直播和重播網絡直播將在我們網站的投資者頁面上提供，網址為 https://ir.harmonybiosciences.com/。</p>
<p><strong>關於 Harmony Biosciences</strong></p>
<p>Harmony Biosciences 是一家致力於為有未滿足醫療需求的罕見神經疾病患者開發和商業化創新療法的製藥公司。Harmony Biosciences 以新穎的科學、遠見的思維和對被忽視者的承諾為動力，培育一個充滿治療可能性的未來，使罕見神經疾病患者能夠真正茁壯成長。公司由 Paragon Biosciences, LLC 於 2017 年成立，總部位於賓夕法尼亞州普利茅斯會議。我們相信，當同情心與創新相遇時，更美好的未來就能開始；這一願景在我們推進的治療創新、我們培養的文化以及我們支持的社區項目中得以體現。欲瞭解更多信息，請訪問 www.harmonybiosciences.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMTAyODc4NDdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMTAyODc4NDdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260210287847/en/</p>
<p><strong>投資者聯繫：</strong> Matthew Beck</p>
<p>astr partners</p>
<p>917-415-1750</p>
<p>matthew.beck@astrpartners.com</p>
<p><strong>媒體聯繫：</strong></p>
<p>Cate McCanless</p>
<p>Harmony Biosciences</p>
<p>202-641-6086</p>
<p>cmccanless@harmonybiosciences.com</p>
<p>來源：Harmony Biosciences Holdings, Inc.</p>

HRMY

<p>Harmony Biosciences Holdings, Inc.（納斯達克代碼：HRMY）將於 2026 年 2 月 24 日美國市場開盤前公佈 2025 年第四季度和全年財務業績。隨後將在東部時間上午 8:30 舉行電話會議和網絡直播，以討論業績。參與者可以撥打 800-274-7083（國內）或 203-518-9786（國際）加入會議，密碼為 HRMYQ425。Harmony Biosciences 專注於開發罕見神經疾病的治療方案</p>

<p>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results.</p>
<div class="lb-trans"><p>賓夕法尼亞州普利茅斯會議——（商業資訊）——Harmony Biosciences Holdings, Inc.（納斯達克：HRMY）今天宣佈，將於 2026 年 2 月 24 日美國金融市場開盤前發佈 2025 年第四季度和全年財務業績。Harmony 將在 2026 年 2 月 24 日上午 8:30（東部時間）召開電話會議和網絡直播，以討論業績。</p>
</div><p>To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call.</p>
<div class="lb-trans"><p>要參加此次電話會議，請撥打 800-274-7083（國內）或 203-518-9786（國際），並引用密碼 HRMYQ425。建議您至少在會議開始前 10 分鐘撥入。</p>
</div><p>The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.</p>
<div class="lb-trans"><p>此次電話會議的直播和重播網絡直播將在我們網站的投資者頁面上提供，網址為 https://ir.harmonybiosciences.com/。</p>
</div><p><strong>About Harmony Biosciences</strong></p>
<div class="lb-trans"><p><strong>關於 Harmony Biosciences</strong></p>
</div><p>Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.</p>
<div class="lb-trans"><p>Harmony Biosciences 是一家致力於為有未滿足醫療需求的罕見神經疾病患者開發和商業化創新療法的製藥公司。Harmony Biosciences 以新穎的科學、遠見的思維和對被忽視者的承諾為動力，培育一個充滿治療可能性的未來，使罕見神經疾病患者能夠真正茁壯成長。公司由 Paragon Biosciences, LLC 於 2017 年成立，總部位於賓夕法尼亞州普利茅斯會議。我們相信，當同情心與創新相遇時，更美好的未來就能開始；這一願景在我們推進的治療創新、我們培養的文化以及我們支持的社區項目中得以體現。欲瞭解更多信息，請訪問 www.harmonybiosciences.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMTAyODc4NDdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260210287847r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260210287847/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260210287847/en/</p>
</div><p><strong>Investor Contact:</strong> Matthew Beck</p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong> Matthew Beck</p>
</div><p>astr partners</p>
<div class="lb-trans"><p>astr partners</p>
</div><p>917-415-1750</p>
<div class="lb-trans"><p>917-415-1750</p>
</div><p>matthew.beck@astrpartners.com</p>
<div class="lb-trans"><p>matthew.beck@astrpartners.com</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫：</strong></p>
</div><p>Cate McCanless</p>
<div class="lb-trans"><p>Cate McCanless</p>
</div><p>Harmony Biosciences</p>
<div class="lb-trans"><p>Harmony Biosciences</p>
</div><p>202-641-6086</p>
<div class="lb-trans"><p>202-641-6086</p>
</div><p>cmccanless@harmonybiosciences.com</p>
<div class="lb-trans"><p>cmccanless@harmonybiosciences.com</p>
</div><p>Source: Harmony Biosciences Holdings, Inc.</p>
<div class="lb-trans"><p>來源：Harmony Biosciences Holdings, Inc.</p>
</div>

Harmony Biosciences 將於2026年2月24日公佈 2025 年第四季度及全年財務業績 | HRMY 股票新聞